

Over the last 7 days, the Biotech industry has risen 7.7%, and 3SBio contributed the most with a gain of 19%. During this same period, the TransThera Sciences (Nanjing) underperformed, falling 7.6%. This takes the industry's 12 month performance to a gain of 125%. Looking forward, earnings are forecast to grow by 40% annually.
Has the Hong Kong Biotech Industry valuation changed over the past few years?
| Date | Market Cap | Revenue | Earnings | PE | Absolute PE | PS |
|---|---|---|---|---|---|---|
| Sun, 16 Nov 2025 | HK$1.0t | HK$68.9b | -HK$12,835,649,578.72 | 39x | -80.8x | 15.1x |
| Tue, 14 Oct 2025 | HK$1.0t | HK$68.3b | -HK$13,109,334,323.71 | 52.9x | -78.4x | 15.1x |
| Thu, 11 Sep 2025 | HK$1.1t | HK$68.5b | -HK$13,530,348,292.59 | 48.9x | -83.1x | 16.4x |
| Sat, 09 Aug 2025 | HK$980.0b | HK$63.8b | -HK$12,369,222,878.15 | 45x | -79.2x | 15.4x |
| Mon, 07 Jul 2025 | HK$806.6b | HK$63.8b | -HK$11,907,882,348.13 | 33.8x | -67.7x | 12.6x |
| Wed, 04 Jun 2025 | HK$652.2b | HK$62.1b | -HK$11,762,332,823.32 | 32.9x | -55.4x | 10.5x |
| Fri, 02 May 2025 | HK$579.2b | HK$60.7b | -HK$11,854,156,442.37 | 29.6x | -48.9x | 9.5x |
| Sun, 30 Mar 2025 | HK$512.2b | HK$55.8b | -HK$14,403,291,832.35 | 40.1x | -35.6x | 9.2x |
| Tue, 25 Feb 2025 | HK$419.3b | HK$52.1b | -HK$17,365,266,124.83 | 14.9x | -24.1x | 8x |
| Thu, 23 Jan 2025 | HK$358.0b | HK$52.2b | -HK$17,353,176,099.26 | 12.5x | -20.6x | 6.9x |
| Sat, 21 Dec 2024 | HK$380.8b | HK$51.9b | -HK$17,231,860,813.06 | 10.7x | -22.1x | 7.3x |
| Mon, 18 Nov 2024 | HK$387.4b | HK$52.4b | -HK$17,431,332,853.71 | 11x | -22.2x | 7.4x |
| Wed, 16 Oct 2024 | HK$383.7b | HK$52.3b | -HK$17,897,072,474.02 | 11.7x | -21.4x | 7.3x |
| Fri, 13 Sep 2024 | HK$345.9b | HK$52.5b | -HK$18,207,260,033.83 | 10.9x | -19x | 6.6x |
| Sun, 11 Aug 2024 | HK$324.3b | HK$50.2b | -HK$19,689,126,009.11 | 11.6x | -16.5x | 6.5x |
| Tue, 09 Jul 2024 | HK$315.4b | HK$49.6b | -HK$19,439,685,151.53 | 11.7x | -16.2x | 6.4x |
| Thu, 06 Jun 2024 | HK$349.7b | HK$49.8b | -HK$19,498,677,857.34 | 10.4x | -17.9x | 7x |
| Sat, 04 May 2024 | HK$371.7b | HK$49.8b | -HK$19,217,324,820.04 | 12.4x | -19.3x | 7.5x |
| Mon, 01 Apr 2024 | HK$342.6b | HK$49.5b | -HK$19,410,823,393.37 | 12.5x | -17.6x | 6.9x |
| Wed, 28 Feb 2024 | HK$352.9b | HK$47.2b | -HK$20,394,488,798.61 | 16.1x | -17.3x | 7.5x |
| Fri, 26 Jan 2024 | HK$338.8b | HK$46.9b | -HK$20,232,006,667.00 | 16.9x | -16.7x | 7.2x |
| Sun, 24 Dec 2023 | HK$386.8b | HK$47.1b | -HK$20,319,677,740.00 | 16.4x | -19x | 8.2x |
| Tue, 21 Nov 2023 | HK$412.4b | HK$46.2b | -HK$18,621,196,244.00 | 18.6x | -22.1x | 8.9x |
| Thu, 19 Oct 2023 | HK$384.0b | HK$44.9b | -HK$19,089,883,268.00 | 12.8x | -20.1x | 8.6x |
| Sat, 16 Sep 2023 | HK$402.1b | HK$45.1b | -HK$18,988,484,078.00 | 15.3x | -21.2x | 8.9x |
| Mon, 14 Aug 2023 | HK$384.0b | HK$35.5b | -HK$23,216,235,923.00 | 25.4x | -16.5x | 10.8x |
| Wed, 12 Jul 2023 | HK$404.6b | HK$35.5b | -HK$23,326,249,602.00 | 25.4x | -17.3x | 11.4x |
| Fri, 09 Jun 2023 | HK$396.1b | HK$35.8b | -HK$23,571,930,156.00 | 25.7x | -16.8x | 11.1x |
| Sun, 07 May 2023 | HK$452.7b | HK$36.7b | -HK$24,346,812,406.00 | 16.5x | -18.6x | 12.4x |
| Tue, 04 Apr 2023 | HK$417.6b | HK$36.0b | -HK$24,260,066,258.00 | 12.2x | -17.2x | 11.6x |
| Thu, 02 Mar 2023 | HK$411.5b | HK$34.7b | -HK$34,985,577,540.00 | 34.4x | -11.8x | 11.9x |
| Sat, 28 Jan 2023 | HK$467.1b | HK$34.9b | -HK$35,243,252,753.00 | 31.3x | -13.3x | 13.4x |
| Mon, 26 Dec 2022 | HK$388.1b | HK$33.6b | -HK$33,898,145,085.00 | 23.2x | -11.4x | 11.6x |
| Wed, 23 Nov 2022 | HK$360.9b | HK$32.9b | -HK$33,106,536,648.00 | 21.8x | -10.9x | 11x |
-10.9x
Which industries have driven the changes within the Hong Kong Healthcare industry?
| HK Market | 1.84% | |
| Healthcare | 5.10% | |
| Biotech | 7.71% | |
| Biotech | 7.71% | |
Which companies have driven the market over the last 7 days?
| Company | Last Price | 7D | 1Y | Valuation | |
|---|---|---|---|---|---|
| 1530 3SBio | HK$34.38 | 19.3% +HK$13.3b | 495.8% | PE31.8x | |
| 6990 Sichuan Kelun-Biotech Biopharmaceutical | HK$465.00 | 13.7% +HK$13.1b | 187.9% | PS66x | |
| 1801 Innovent Biologics | HK$92.25 | 8.3% +HK$12.1b | 148.0% | PE127.5x | |
| 9926 Akeso | HK$118.80 | 5.9% +HK$6.1b | 72.8% | PS39.8x | |
| 9606 Duality Biotherapeutics | HK$338.60 | 18.8% +HK$4.7b | n/a | PS12.5x |